Germany's Merck says it's "on track to achieve objectives for 2018"

German pharma, science and technology company Merck KGaA (MRK: DE) today informed analysts and investors at its 2016 Capital Market Day about the progress it has made in achieving its objectives up to the year 2018.

In addition, chief executive and chairman of the executive board Stefan Oschmann and chief financial officer Marcus Kuhnert provided a look at the period after 2018, the year which marks the company’s 350th anniversary.

Mr Oschmann stated: “We firmly believe that we will meet the objectives we have set for 2018. We have focused our pharmaceutical pipeline and continuously developed it further. Currently, we have one product in regulatory review. We are vigorously driving the integration of Sigma-Aldrich forward and expect to even exceed the originally planned synergies since additional top-line synergies are being generated. Our Performance Materials business is well-positioned to capture attractive new markets. At Group level, we are aiming to swiftly reduce our debt from the Sigma-Aldrich acquisition.”